Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

339
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
339
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

933
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
933
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

888
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
888
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

968
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
968
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

316
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
316

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circumstances and triggering factors for major arrhythmic events in Brugada Syndrome patients without spontaneous type 1 ST elevation.

Heart rhythm·2026
Same author

Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study.

ESC heart failure·2026
Same author

Early complications and long-term outcome of patients treated with a Subcutaneous Cardioverter-Defibrillator: temporal trends and clinical implications of the anesthetic strategies adopted at implant.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Determinants and outcomes of late electrical storm in patients supported by left ventricular assist device.

Heart rhythm·2026
Same author

One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Duration of heart failure as a determinant of outcomes after left ventricular assist device implantation: an international multicenter study.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Electrical therapies for heart failure

Christophe Leclercq1, Nathalie Béhar1, Raphaël Martins1

  • 1Département de cardiologie et maladies vasculaires, centre cardio-pneumologique, CHU de Rennes, CIC-IT 804, université de Rennes I, Rennes, France.

La Revue Du Praticien
|December 5, 2018
PubMed
Summary

Electrical therapies like defibrillators and resynchronization improve outcomes for heart failure patients with reduced ejection fraction. These treatments should complement, not replace, optimized medical therapy.

Keywords:
heart failurecardiac resynchronization therapy

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Related Experiment Videos

Last Updated: Feb 1, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Area of Science:

  • Cardiology
  • Biomedical Engineering

Context:

  • Heart failure with reduced left ventricular function is a significant clinical challenge.
  • Pharmacological treatment is the primary therapy for heart failure.

Purpose:

  • To outline the role of electrical therapies in managing heart failure patients with reduced ejection fraction.
  • To detail indications for implantable cardioverter-defibrillators and cardiac resynchronization therapy.

Summary:

  • Intracardiac cardioverter-defibrillators are indicated for primary and secondary prevention of sudden cardiac death due to ventricular arrhythmias.
  • Cardiac resynchronization therapy improves symptoms, function, survival, and reduces hospitalizations in specific heart failure patients, particularly those with left bundle branch block.
  • Both electrical therapies are recommended after optimization of medical management.

Impact:

  • Enhances patient survival and quality of life in heart failure.
  • Reduces hospitalizations and healthcare resource utilization.
  • Provides a framework for integrating advanced electrical therapies into heart failure management protocols.